FeesSafety
Pluang+

Fantom backer Harry Yeh dies after falling from Paraguay tower, investigation ongoing.

Market News
10 Aug 2026
Crypto Briefing
View Source
Bearish
Fantom backer Harry Yeh dies after falling from Paraguay tower, investigation ongoing.

Harry Yeh, founder of Quantum Fintech and key supporter of the Fantom ecosystem, died after falling from the 30th floor of a high-rise in Asunción, Paraguay. Authorities are investigating the cause, considering accident, suicide, or homicide, with forensic exams underway. Yeh managed over $2.4 billion in assets and was involved in several DeFi projects linked to Fantom. The impact on the Fantom ecosystem and Quantum Fintech's management remains uncertain as the investigation continues.

More News

CHMP recommends approval of Johnson & Johnson's TALVEY plus daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

CHMP recommends approval of Johnson & Johnson's TALVEY plus daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...

Market News
Bullish
3 hours ago
CHMP recommends approval of Johnson & Johnson's TALVEY® plus daratumumab for earlier treatment of relapsed multiple myeloma

CHMP recommends approval of Johnson & Johnson's TALVEY® plus daratumumab for earlier treatment of relapsed multiple myeloma

The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...

Market News
Bullish
3 hours ago
CHMP recommends approval of Johnson & Johnson's TALVEY® with daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

CHMP recommends approval of Johnson & Johnson's TALVEY® with daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...

Market News
Bullish
3 hours ago
Fortrea and Omico partner to accelerate biomarker-led cancer drug trials in Australia

Fortrea and Omico partner to accelerate biomarker-led cancer drug trials in Australia

Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...

Market News
Bullish
4 hours ago
Fortrea and Omico partner to speed biomarker-based cancer drug trials in Australia

Fortrea and Omico partner to speed biomarker-based cancer drug trials in Australia

Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App